Effect of Intralesional Triamcinolone combined with Pentoxifylline versus Intralesional Triamcinolone alone in the treatment of Keloid

A Hospital-Based Randomized Controlled Trial comparing the Efficacy of Intralesional Triamcinolone combined with Pentoxifylline versus Intralesional Triamcinolone alone in the treatment of Keloid - nil

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/07/090637

Enrollment

Registered

2025-07-10

Start date

Unknown

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L918- Other hypertrophic disorders of the skin

Interventions

Intervention1: Intralesional Triamcinolone acetonide combined with Pentoxifylline: Intralesional Triamcinolone acetonide combined with Pentoxifylline monthly sessions for 6 months.the total duration

Eligibility

Inclusion criteria

Inclusion criteria: 1.Age between 18 and 60 years. 2.Presence of clinically diagnosed keloid(s) persisting for at least 6 months. 3.Willing to adhere to the study protocol and complete follow-up assessments. 4.Keloid size between 0.5 cm and 8 cm in diameter. 5.No treatment with intralesional injections within the past 1 month.

Exclusion criteria

Exclusion criteria: 1.Active local skin infections or ulceration at the treatment site. 2.History of hypertrophic scar rather than keloid. 3.Known hypersensitivity to triamcinolone or pentoxifylline. 4.Patients with immunosuppressive or systemic corticosteroid therapy. 5.Patients with systemic illness such as uncontrolled diabetes, liver/kidney dysfunction. 6.Pregnant or lactating women. 7.Bleeding diathesis or anticoagulant use. 8.History of epilepsy, peptic ulcer, or recent myocardial infarction (contraindications for pentoxifylline). 9.Participation in another clinical trial within the last 3 months

Design outcomes

Primary

Measure	Time frame
Decrease in Vancouver Scar Scale (VSS) score Assessment of vascularity, pigmentation, pliability, and height.Timepoint: At 0, 6 and 12 months.	—

Secondary

Measure	Time frame
1.Percentage reduction in keloid size (surface area and thickness) 2.Global photographic assessment Standardized photos evaluation 3.Symptom evaluation Pain and pruritus assessed at every visit using Visual Analog Scale (VAS). 4.Adverse events Monitoring of both local and systemic side effects such as skin atrophy, depigmentation, ulceration, and systemic reactions (e.g., GI upset from pentoxifylline). Timepoint: for keloid size and photographic assessment- 0,6,12 months for symptoms and adverse events - every monthly visit	—

Measure

Time frame

1.Percentage reduction in keloid size (surface area and thickness) 2.Global photographic assessment Standardized photos evaluation 3.Symptom evaluation Pain and pruritus assessed at every visit using Visual Analog Scale (VAS). 4.Adverse events Monitoring of both local and systemic side effects such as skin atrophy, depigmentation, ulceration, and systemic reactions (e.g., GI upset from pentoxifylline). Timepoint: for keloid size and photographic assessment- 0,6,12 months for symptoms and adverse events - every monthly visit

—

Countries

India

Contacts

Public ContactRavi Daiya

ALL INDIA INSTITUTE OF MEDICAL SCIENCES GORAKHPUR

dr.sunil_30@yahoo.co.in9838844937

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026